Efficacy assessments
cancer, ovarian cancer, Tumor
GLIOBLASTOMA, CANCER, OVARIAN CANCER, TUMOR
Tumor assessments by radiological examination (computed tomography / magnetic resonance imaging scans) and cancer antigen 125 monitoring (in ovarian cancer patients) were performed at screening and end of study, and within the 7 days prior to completion of every even-numbered cycle, before administration of the next cycle of lisavanbulin. Tumor response was evaluated according to RECIST v1.1 (ovarian cancer) or RANO criteria (glioblastoma). Complete response or partial response had to be present for at least 4 weeks to be assessed as confirmed. Each lesion measured at baseline was to be measured throughout the study by the same method of assessment and the same technique, to facilitate consistent assessments and comparisons. Tumor growth was expressed as the change from baseline in the sum/products of the perpendicular diameters for either the target lesion or all measurable enhancing lesions.